Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure types.
### Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Adjunctive treatment of other seizure types (efficacy and safety beyond LGS in pediatrics is not well established).
### Adult Dosing
* **Lennox-Gastaut Syndrome (LGS):** The recommended starting dose is 5 mg twice daily. The dose may be increased by 5-10 mg every week based on clinical response and tolerability, up to a maximum of 20 mg twice daily.
* **Other Seizure Types:** Dosing is highly individualized and may depend on local protocols.
### Pediatric Dosing
* **LGS (2 to less than 10 years of age):** The recommended starting dose is 5 mg once daily. The dose may be increased by 2.5-5 mg every week based on clinical response and tolerability, up to a maximum of 10 mg twice daily.
* **LGS (10 years of age and older):** The recommended starting dose is 5 mg twice daily. The dose may be increased by 5-10 mg every week based on clinical response and tolerability, up to a maximum of 20 mg twice daily.
* **Other Seizure Types:** Dosing is highly individualized and may depend on local protocols.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are established, but lower doses may be considered.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic impairment.
### Adverse Effects
Common adverse effects include somnolence, decreased appetite, constipation, aggression, irritability, and vomiting. Serious adverse effects include severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, withdrawal symptoms, and respiratory depression.
### Key Drug Interactions
* **Central Nervous System (CNS) Depressants:** Additive CNS depression with alcohol, opioids, other benzodiazepines, sedating antihistamines, and antipsychotics.
* **CYP3A4 Inhibitors/Inducers:** Clobazam is metabolized by CYP3A4. Inhibitors may increase clobazam levels, and inducers may decrease them.
* **Antiepileptic Drugs (AEDs):** Clobazam can affect levels of other AEDs, and vice versa. Monitor AED levels as clinically indicated.
### Monitoring
* Monitor for efficacy in seizure control.
* Monitor for signs and symptoms of serious adverse effects, including skin reactions, suicidal behavior, and withdrawal.
* Monitor for excessive sedation or CNS depression.
* Monitor for potential drug interactions, especially with other CNS depressants and AEDs.
### Clinical Pearls
* Clobazam has a longer half-life compared to some other benzodiazepines, which may allow for less frequent dosing in some patients.
* Tapering of the dose is recommended upon discontinuation to avoid withdrawal symptoms.
* The risk of serious skin reactions requires vigilance and prompt discontinuation if suspected.
***
*This information is intended for clinical use and does not replace professional medical advice. Always refer to the most current prescribing information and consult with a healthcare provider for specific patient management decisions.*
